RXRX
Recursion Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
4.03
close · 2026-10-30
value
30
cheaper than peers30
quality
21
stronger fundamentals21
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.36× | 65 |
| cash flow yield, 3 years ago | -5.0% | 59 |
| cash flow yield, 2 years ago | -12.5% | 43 |
| cash flow yield, latest year | -15.8% | 40 |
| cash flow yield, 1 year ago | -15.6% | 40 |
| earnings yield, 3 years ago | -33.7% | 36 |
| earnings yield, 2 years ago | -39.2% | 35 |
| earnings yield, 1 year ago | -41.9% | 31 |
| earnings yield, latest year | -35.7% | 30 |
| price to sales | 43.92× | 24 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 7.3% | 68 |
| return on equity | -56.6% | 44 |
| revenue growth | -60.1% | 17 |
| operating margin | -1759.7% | 14 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$219.5M |
| employees | 600 |
| first trade | 2021-04-16 |
| next earnings | 2026-11-02 |
| fundamentals updated | 2026-08-31 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.44 | -1.69 | -1.58 | -1.36 | not reported |
| free cash flow | -$380.4M | -$376.2M | -$300.3M | -$120.9M | not reported |
| net income | -$644.8M | -$463.7M | -$328.1M | -$239.5M | not reported |
| revenue | $74.3M | $58.5M | $43.9M | $39.7M | not reported |
| unusual items | not reported | not reported | $0 | $0 | -$827,000 |